At a statutory Board meeting following an Extraordinary General Meeting on April
22, 2013 in Mertiva AB (previously Diamyd Medical AB), Andreas Bergsten was
appointed as the Chief Executive Officer of the Company.
Andreas Bergsten, born in 1967, is currently working as a consultant in finance
and management and has, in his capacity as a consultant, primarily worked for
venture capital and private equity firms. In the past, Andreas has served as CFO
of four different companies and, prior to this, he was employed at Citigroup,
initially as a financial analyst and subsequently as a relationship manager.
Andreas holds a Master of Science in Business and Economics from the Stockholm
School of Economics and the McGill University MBA Program.
For more information, please contact:
info@mertiva.se
About Mertiva
Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid
assets and holdings in Protein Sciences Corporation and Mercodia AB.
Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small
Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY)
administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).
More information can be found at www.mertiva.se
This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.
Mertiva AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden.
E-mail: info@mertiva.com. Reg. no: 556530-1420
